Vyne Therapeutics Inc
$ 0.58
-3.55%
24 Feb - close price
- Market Cap 19,852,000 USD
- Current Price $ 0.58
- High / Low $ 0.60 / 0.57
- Stock P/E N/A
- Book Value 1.01
- EPS -0.79
- Next Earning Report 2026-03-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.42 %
- ROE -0.71 %
- 52 Week High 2.75
- 52 Week Low 0.28
About
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing and commercializing various therapies for dermatology. The company is headquartered in Bridgewater, New Jersey.
Analyst Target Price
$2.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-14 | 2025-05-07 | 2025-02-26 | 2024-11-11 | 2024-08-14 | 2024-05-09 | 2024-02-29 | 2023-11-13 | 2023-08-14 | 2023-05-11 | 2023-03-09 |
| Reported EPS | -0.17 | -0.13 | -0.2 | -0.2822 | -0.29 | -0.22 | -0.15 | -0.2 | -2.01 | -3.09 | -1.74 | -3.33 |
| Estimated EPS | -0.3 | -0.29 | -0.29 | -0.3033 | -0.23 | -0.19 | -0.24 | -0.5 | -0.76 | -1.99 | -2.61 | -3.24 |
| Surprise | 0.13 | 0.16 | 0.09 | 0.0211 | -0.06 | -0.03 | 0.09 | 0.3 | -1.25 | -1.1 | 0.87 | -0.09 |
| Surprise Percentage | 43.3333% | 55.1724% | 31.0345% | 6.9568% | -26.087% | -15.7895% | 37.5% | 60% | -164.4737% | -55.2764% | 33.3333% | -2.7778% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-05 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.2 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: VYNE
2026-01-30 21:31:39
VYNE Therapeutics has amended its merger agreement with Yarrow Bioscience to allow for the issuance of pre-funded warrants to Yarrow stockholders exceeding beneficial ownership limits and to clarify dividend eligibility for VYNE common stock and certain warrant holders. These changes, signed on January 30, 2026, aim to streamline the merger's closing and ensure regulatory compliance.
2025-12-19 14:09:13
The Ademi Firm is investigating VYNE Therapeutics Inc. (Nasdaq: VYNE) regarding a possible breach of fiduciary duty concerning its transaction with Yarrow Bioscience. In this deal, pre-Merger VYNE stockholders are expected to own only approximately 3% of the combined company, while Yarrow stockholders will own 97%. The investigation aims to determine if VYNE's board of directors is fulfilling its fiduciary duties to all shareholders, especially given the disproportionate ownership split and potential benefits for VYNE insiders.
2025-12-19 01:09:53
The Ademi Firm is investigating VYNE Therapeutics Inc. (Nasdaq: VYNE) regarding a recently announced transaction with Yarrow Bioscience, questioning whether the deal offers a fair price to VYNE public shareholders. VYNE shareholders are expected to own approximately 3% of the combined company, while Yarrow stockholders will own 97%, with VYNE insiders receiving substantial benefits. The firm is examining potential breaches of fiduciary duty by VYNE's board of directors.
2025-12-19 01:09:53
The Ademi Firm is investigating VYNE Therapeutics Inc. (Nasdaq: VYNE) due to concerns about the fairness of its recently announced transaction with Yarrow Bioscience. Shareholders of pre-merger VYNE are expected to own only approximately 3% of the combined company, while Yarrow stockholders will own 97%. The investigation focuses on whether VYNE's board of directors is fulfilling its fiduciary duties to all shareholders, especially given that VYNE insiders will receive substantial benefits and the agreement includes a significant penalty for competing bids.
2025-12-18 19:39:00
The Ademi Firm is investigating VYNE Therapeutics Inc. (Nasdaq: VYNE) for potential breaches of fiduciary duty related to its transaction with Yarrow Bioscience. In this deal, pre-merger VYNE stockholders will own only about 3% of the combined company, while Yarrow stockholders will own 97%. The investigation focuses on whether VYNE's board is fulfilling its duties to shareholders, especially given a significant penalty clause for competing bids and substantial benefits for VYNE insiders.
2025-12-18 14:09:53
Vyne Therapeutics Inc (NASDAQ:VYNE) stock dramatically increased by 77.9% in premarket trading following the announcement of its definitive merger agreement with Yarrow Bioscience. This all-stock transaction will result in the combined company operating as Yarrow Bioscience, trading under "YARW" on Nasdaq, and is supported by approximately $200 million in pre-closing financings. The merger is expected to provide value to stockholders through a cash dividend and advance Yarrow's therapies for thyroid autoimmune diseases.
